Ichor Biologics
Ichor Biologics is a New York City-based pre-clinical biotechnology company specializing in the rapid development of antibody-based therapeutics against infectious diseases. The company has developed a novel high-throughput platform that isolates and characterizes naturally occurring human monoclonal antibodies, leveraging human immune resistance to infectious pathogens. Their technology integrates novel assays to identify protective immune responses, innovative antigen production methods, and proprietary machine learning software to enhance antibody efficacy. Ichor aims to advance antibody therapeutics through preclinical validation to establish strategic partnerships or licensing deals, focusing on deadly infectious diseases such as hantavirus infections. The company has demonstrated efficacy in animal models and received significant NIH and government grants, positioning it as a promising player in infectious disease therapeutics.
Ichor Biologics
Ichor Biologics is a New York City-based pre-clinical biotechnology company specializing in the rapid development of antibody-based therapeutics against infectious diseases. The company has developed a novel high-throughput platform that isolates and characterizes naturally occurring human monoclonal antibodies, leveraging human immune resistance to infectious pathogens. Their technology integrates novel assays to identify protective immune responses, innovative antigen production methods, and proprietary machine learning software to enhance antibody efficacy. Ichor aims to advance antibody therapeutics through preclinical validation to establish strategic partnerships or licensing deals, focusing on deadly infectious diseases such as hantavirus infections. The company has demonstrated efficacy in animal models and received significant NIH and government grants, positioning it as a promising player in infectious disease therapeutics.